Biological therapy in systemic lupus erythematosus. Is there life beyond the B cell?;Terapia biológica en el lupus eritematoso sistémico. ¿Hay vida más allá del linfocito B?

Seminarios de la Fundacion Espanola de Reumatologia

Volumn 12, Issue 2, 2011, Pages 50-52

  Otón, Teresa ^a   Fernández Castro, Mónica ^a   Silva Fernández, Lucía ^a   Andreu, José Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Abatacept; Biologic therapy; Infliximab; Systemic lupus erythematosus; Tocilizumab

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; DNA ANTIBODY; INFLIXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; BIOLOGICAL THERAPY; HUMAN; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 79955713604     PISSN: 15773566     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semreu.2010.08.001     Document Type: Short Survey

References (19)

1. Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus an open-label study. Arthritis Rheum. 2004, 50:3161-3169.
2. Katz R.S., Holt-Daly N., MacDonald P.A. Frequent infusion reactions associated with infliximab treatment in patients with polyarthritis related to systemic lupus erythematosus [abstract]. Arthritis Rheum. 2003, 48:S379.
3. Aringer M., Smolen J.S. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. 2008, 10:202-209.
4. Carlson E., Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003, 48:1165-1166.
5. Mor A., Bingham I.I.I.C., Barisoni L., Lydon E., Belmont H.M. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005, 32:740-743.
6. Stokes M.B., Foster K., Markowitz G.S., Ebrahimi F., Hines W., Kaufman D., et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005, 20:1400-1406.
7. TNF blockade with Remicade in active lupus nephritis WHO class V (trial). Disponible en: http://www. clinicaltrials.gov/ct2/show/NCT00368264?term 1/4 infliximab{thorn}SLE&rank 1/4. US National Institutes of Health, ClinicalTrials. gov [on line] [consultado 4/6/2010] http://www.clinicaltrials.gov/.
8. Etanercept for the treatment of lupus nephritis. Disponible en: http//:www.clinicaltrials.gov/ct2/show/NCT00447265?term 1/4 SLE{thorn}etanercept&rank 1/4. US National Institutes of Health, ClinicalTrials. gov [on line] [consultado 4/6/2010] http://www.clinicaltrials.gov/.
9. Gröndal G., Gunnarsson I., Rönnelid J., Rogberg S., Klareskog L., Lundberg I., et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000, 18:565-570.
10. Llorente L., Richaud-Patin Y., García-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43:1790-1800.
11. Davidson A., Diamond B., Wofsy D., Daikh D. Block and trackle: CTLA4Ig takes on lupus. Lupus. 2005, 14:197-203.
12. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006, 144:865-876.
13. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005, 353:1114-1123.
14. Merrill J.T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D.J., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087.
15. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: innovating therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007, 30:2001-2006.
16. Ripley B.J., Goncalves B., Isenberg D.A., Latchman D.S., Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis. 2005, 64:849-853.
17. Tsai C.Y., Wu T.H., Yu C.L., Lu J.Y., Tsai Y.Y. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000, 85:207-214.
18. Shirota Y., Yarboro C., Sims G., Fritsch R., Ettinger R., Valencia X., et al. The impact of in vitro anti-interleukin 6 receptor blockade on circulating T and B-cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 52:S697.
19. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010, 62:542-552.